Fisetin: The Complete Evidence-Based Guide
Fisetin (3,3′,4′,7-tetrahydroxyflavone) is a naturally occurring flavonoid — a plant polyphenol found in various fruits and vegetables. It belongs to the same family of compounds as quercetin and kaempferol, but has emerged from the scientific literature as the most potent of its class in one critical area: clearing senescent cells, the biological phenomenon now understood to be a primary driver of aging. The compound is not new to biochemistry. Research on fisetin's antioxidant properties dates back decades. But the scientific landscape around fisetin shifted dramatically after a landmark 2018 study from Mayo Clinic and Scripps Research published in EBioMedicine — which tested 46 natural and synthetic compounds for senolytic activity and found fisetin to be the strongest natural candidate.
What Is Fisetin? A Science-Based Introduction
Fisetin is a naturally occurring flavonoid — a type of polyphenolic plant compound — found in a variety of common fruits and vegetables. It belongs to the flavonol subclass, which also includes quercetin and kaempferol. The compound was first isolated in 1891 from the smoke tree, but significant scientific attention began in the early 2000s.
How Fisetin Works: Senolytic & Anti-Inflammatory Mechanisms
Fisetin's primary mechanism of research interest is its senolytic activity — the ability to selectively clear senescent cells. In a 2018 screening study, researchers at Mayo Clinic tested 10 flavonoids and fisetin emerged as the most potent, reducing senescent cell viability by approximately 50–70% in cell culture.
Fisetin Benefits: What the Evidence Shows
This page provides an evidence-graded summary of what preclinical research and early human studies suggest about fisetin supplementation. The vast majority of evidence remains preclinical, with human evidence classified as early-stage/emerging.
Fisetin Side Effects & Safety: Evidence Summary
This page summarizes what is currently known about fisetin safety from published clinical data, preclinical toxicology studies, and dietary exposure history. While fisetin has a long history of consumption through foods, its safety profile at supplemental doses (100–2000 mg) is less well-characterized.
Fisetin Dosage: Research Summary & Clinical Doses Used
There is no established recommended dosage for fisetin. Unlike pharmaceutical drugs that undergo Phase III dose-finding trials, fisetin dosing in research has been exploratory and varies significantly between studies. This page summarizes the doses that have been used in published and registered human clinical trials.
Fisetin Dosage by Weight: Calculation Chart for Research Protocols
A walk-through of how fisetin dosage by weight works in research settings — the mg/kg formula, pounds-to-kilograms conversion, a dosage chart for 10 and 20 mg/kg, worked examples for common body weights, and why clinical-trial doses should not be copied by supplement users.
What Does 20 mg/kg of Fisetin Mean? Weight-Based Examples Explained
A walk-through of what 20 mg/kg of fisetin means in published and registered research: the mg/kg formula, worked weight-based examples, a 50–100 kg dosage table, a pounds-to-kilograms conversion table, the 70 kg example, why this figure appears in clinical trials, and why it should not be copied as a supplement dose.
Fisetin Dose Calculator: Convert Weight-Based Research Doses
An interactive tool to convert research-style fisetin mg/kg values into milligrams using body weight, plus a full explanation of how the formula works, worked examples, evidence limitations, and why trial doses should not be copied as consumer doses.
Can You Take Fisetin Every Day? What Human Research Actually Shows
A review of daily versus intermittent fisetin dosing in human research, covering registered daily-use trials, pulse-dose senolytic protocols, supplement-label variation, long-term safety evidence, animal-study limitations, and who should seek medical advice.
Fisetin Pulse Dosing vs Daily Dosing: What Is the Difference?
How fisetin daily dosing, pulse dosing, intermittent dosing, and repeated monthly cycles differ, which human studies tested each schedule, why the timing matters as much as the milligram amount, and the limitations of the current evidence.
How Much Fisetin Should You Take Daily? Research, Labels and Limitations
A review of why there is no established daily fisetin dosage, how commercial label amounts compare to studied doses, the daily regimens tested in humans, weight-based short-duration protocols, and what to discuss with a clinician.
Fisetin Bioavailability: Why Formulation Matters
Bioavailability — the fraction of an ingested substance that reaches systemic circulation — is one of the most significant challenges in fisetin research. Like many flavonoids, fisetin has very low oral bioavailability, which raises fundamental questions about whether oral supplementation can achieve the tissue concentrations shown to be active in cell culture experiments.
Fisetin: Foods vs Supplements — What You Need to Know
Fisetin is naturally present in several common fruits and vegetables, leading to a natural question: can dietary sources provide enough fisetin to achieve the effects seen in research? This page compares dietary fisetin intake from food sources with supplemental doses used in clinical trials.
Fisetin Clinical Trials: Complete Human Study and Results Tracker
A structured overview of the current fisetin human evidence base: completed trials with published results, registry-result-only records, recruiting and active trials, terminated studies, unclear-status records, why registration is not proof of efficacy, and major unanswered questions.
What Fisetin Doses Have Human Clinical Trials Used?
Which fisetin doses and schedules have actually been used in human studies, why they differ so widely, the difference between fixed and weight-based dosing, daily versus intermittent schedules, and why a trial dose is not a consumer recommendation.
Fisetin Human Studies: What Has Actually Been Proven?
The current strength and quality of fisetin human evidence, what has been demonstrated in people versus animals or cells, why formulation matters, what remains unproven, and which anti-aging and senolytic claims are not supported by human data.
Is High-Dose Fisetin Safe? Human Evidence and Important Unknowns
How to define a high fisetin dose, why human data cannot yet set a maximum safe dose, what the published adverse-event record shows, why short trial pulses differ from regular unsupervised use, and the warning signs that warrant medical attention.
Fisetin Side Effects, Drug Interactions and Safety Considerations
The current human adverse-event record for fisetin, why small studies cannot prove long-term safety, how to interpret trial exclusion criteria, and which medical contexts warrant clinical review before starting fisetin.
Should You Take Fisetin With Food or on an Empty Stomach?
What is known about fisetin absorption, why poor solubility makes timing advice uncertain, whether dietary fat helps, what the 2022 crossover PK study found, and how standard, liposomal, micellar, and nano formulations differ in human evidence.
Fisetin Bioavailability: Absorption, Metabolism and Formulation Differences
What bioavailability means, why fisetin has a delivery problem, how phase II metabolism changes circulating forms, why a lower dose of one formulation can outperform a larger unformulated dose, and what remains unproven about enhanced formulations.
Fisetin vs Quercetin: Senolytic Evidence, Dosage and Key Differences
How fisetin and quercetin differ chemically, which has stronger standalone senolytic cell evidence, why human trials are not directly comparable, how research doses differ, and why neither has proven human anti-aging efficacy.
Fisetin vs Spermidine: Senolytics, Autophagy and Healthy-Aging Research
Why fisetin is framed as a senolytic candidate while spermidine is framed as an autophagy-related polyamine, what human studies exist for each, how their doses differ, and why combining them is not clinically proven.
Fisetin FAQ: Common Questions Answered
This FAQ compiles the most commonly asked questions about fisetin, drawing from published research, clinical trial data, and expert commentary. Each answer is grounded in the current evidence base and clearly notes where evidence is limited or absent.
Fisetin & Healthy Aging: What Research Shows
Healthy aging is the overarching research context for fisetin investigation. Rather than targeting a single disease, researchers hypothesize that fisetin's senolytic and anti-inflammatory activities could broadly improve age-related tissue function by reducing the burden of senescent cells — a hallmark of biological aging. This page summarizes evidence from preclinical models and early human studies investigating fisetin in the context of healthy aging. It is critical to note that while the biological rationale is compelling, human evidence remains early-stage and no anti-aging claims are supported by published clinical data.
Fisetin & Cellular Senescence: Senolytic Evidence
Cellular senescence — the permanent growth arrest of damaged cells combined with resistance to apoptosis — is the primary biological pathway through which fisetin is studied. Senolytic agents are compounds that selectively eliminate these accumulated senescent cells. Fisetin's identification as a potent senolytic in 2018 transformed it from a relatively obscure flavonoid into one of the most-discussed dietary compounds in aging research. This page reviews the evidence for fisetin's senolytic activity across different experimental systems and discusses the gap between in vitro/animal findings and human clinical translation.
Fisetin & Vascular Function: Clinical Trial Evidence
Vascular function represents one of the most actively investigated clinical applications of fisetin. The rationale connects senescent cell accumulation in vascular endothelium with age-related arterial stiffening and endothelial dysfunction — key contributors to cardiovascular risk in older adults. A randomized clinical trial (NCT06133634) specifically studying fisetin for vascular function in adults aged 60–85 began enrollment in 2024. This represents one of the first rigorous human studies with functional vascular endpoints.
Fisetin & Inflammatory Biomarkers: Research Summary
Chronic low-grade inflammation — often termed 'inflammaging' — is a hallmark of biological aging and a contributor to age-related diseases including cardiovascular disease, type 2 diabetes, neurodegeneration, and cancer. Fisetin has been studied for its ability to modulate inflammatory biomarkers through multiple pathways, both directly (NF-κB inhibition) and indirectly (senescent cell clearance). This page reviews the evidence for fisetin's effects on specific inflammatory biomarkers and discusses what this data means for clinical application.
Fisetin & Frailty: Emerging Research
Frailty is a clinical syndrome characterized by decreased physiological reserve and increased vulnerability to stressors. It is strongly associated with aging and represents a major public health challenge as populations age. Researchers hypothesize that senescent cell accumulation may contribute to frailty development, making senolytics a theoretical intervention target. This page reviews the biological rationale for studying fisetin in frailty contexts and the status of related clinical research.
Fisetin & Neuroprotection: Preclinical Evidence
Fisetin has been studied in preclinical models of neurodegeneration and cognitive aging, showing effects on neuroinflammation, oxidative stress, and memory performance in animal models. It is essential to emphasize that all neuroprotective evidence for fisetin is preclinical — no human trial has demonstrated cognitive or neuroprotective benefits. This page provides context for the preclinical neuroprotection literature while clearly delineating the boundary between animal model findings and any potential clinical relevance.
Fisetin & Cancer Research: Preclinical Context
Fisetin has been extensively studied in preclinical cancer research, showing anti-proliferative, pro-apoptotic, and anti-angiogenic effects across numerous cancer cell lines and animal tumor models. This page provides context for that research while making absolutely clear that fisetin is not a cancer treatment and should never be used as a substitute for evidence-based oncology care. IMPORTANT DISCLAIMER: Fisetin has not been shown to treat, cure, or prevent cancer in humans. No human cancer trial with fisetin has been published. This page is for educational context only.
Fisetin Bioavailability Limitations: Research Overview
Bioavailability is arguably the most significant scientific challenge in fisetin research. The gap between concentrations shown to be biologically active in cell culture (10-100 μM) and those achievable in human plasma after oral dosing (low μM to nM range) undermines the translational relevance of much of the preclinical evidence base. This page provides a detailed examination of fisetin's bioavailability limitations, the pharmacokinetic data available, and the delivery technologies being investigated to overcome these challenges.
Fisetin & Brain Health: Cognitive Function Research
Among flavonoids, fisetin is unusual because it readily crosses the blood-brain barrier and reaches the brain after oral dosing. This property has driven extensive preclinical research into its potential neuroprotective and cognition-supporting effects. This page summarizes the evidence on fisetin and brain health, including memory and learning studies in rodents, neurodegenerative disease models, and the critical translational limitations. No human trial has measured cognitive outcomes with fisetin.
Fisetin & Skin Health: Anti-Aging Dermatology Research
Skin is one of the most accessible tissues for studying aging, and several preclinical studies have examined fisetin's effects on skin cells and UV damage models. Fisetin's antioxidant, anti-inflammatory, and senolytic properties are all theoretically relevant to skin aging. This page reviews the evidence on fisetin and skin health, including wrinkle formation, UV protection, collagen preservation, and senescent cell clearance in skin. No human clinical trial has validated fisetin for dermatological anti-aging.
Fisetin & Metabolic Health: Blood Sugar & Diabetes Research
Metabolic health — encompassing blood sugar regulation, insulin sensitivity, and type 2 diabetes — is a major focus of aging research, and fisetin has been studied in several preclinical metabolic disease models. The biological rationale is strong: chronic inflammation, oxidative stress, and cellular senescence all contribute to metabolic dysfunction. This page reviews the evidence on fisetin and metabolic health, including diabetic mouse model studies, proposed mechanisms, and the absence of human clinical data. No one should use fisetin as a substitute for evidence-based diabetes care.
Fisetin & Heart Health: Cardiovascular Research
Cardiovascular disease remains the leading cause of death globally, and aging is the primary risk factor. Fisetin's senolytic, anti-inflammatory, and antioxidant properties are all theoretically relevant to heart and vascular health. This page reviews the evidence on fisetin and cardiovascular health, including preclinical cardioprotection studies, the ongoing human vascular function trial (NCT06133634), and the absence of clinical cardiovascular outcome data. No one should use fisetin as a substitute for evidence-based cardiovascular care.
Fisetin & Longevity: Lifespan Research
Lifespan extension is the most attention-grabbing finding in fisetin research. The 2018 Yousefzadeh et al. study showed that late-life fisetin treatment extended both median and maximum lifespan in naturally aging mice by approximately 10%. This page examines the lifespan evidence, the NIA Interventions Testing Program context, the translational limitations, and why mouse lifespan findings rarely translate to human longevity. No human evidence supports fisetin for extending human lifespan.
Fisetin vs Quercetin: Senolytic & Antioxidant Comparison
Fisetin and quercetin are both dietary flavonols studied as senolytics, but their evidence profiles differ. In the 2018 Mayo Clinic screening, fisetin showed the strongest senolytic potency among 10 flavonoids tested. Quercetin's senolytic clinical data, however, comes almost entirely from its combination with dasatinib (D+Q) — which has published human trials in diabetic kidney disease and idiopathic pulmonary fibrosis. This page compares their mechanisms, safety, bioavailability, and evidence maturity.
Fisetin vs Urolithin A: Mechanism & Evidence Differences
Fisetin and Urolithin A address two different hallmarks of aging. Fisetin is a senolytic that clears senescent 'zombie' cells via BCL-xL inhibition. Urolithin A is a mitophagy activator that recycles damaged mitochondria. They are complementary rather than competing. Urolithin A has substantially more published human clinical data, including RCTs with functional outcomes and FDA GRAS status.
Fisetin vs Curcumin: Anti-Inflammatory Polyphenol Comparison
Fisetin and curcumin are both polyphenols with very poor oral bioavailability, but they have different primary research interests and very different evidence volumes. Fisetin is studied mainly as a senolytic (clearing senescent cells); curcumin is studied mainly for anti-inflammatory effects (NF-κB, COX-2 inhibition). Curcumin has thousands of published studies vs. fewer than 200 for fisetin, though many curcumin trials have methodological limitations.
Fisetin vs Resveratrol: Polyphenol Comparison for Aging Research
Fisetin and resveratrol are both polyphenols studied for anti-aging effects via different mechanisms (fisetin: BCL-xL senolytic; resveratrol: SIRT1 activation). Resveratrol has a longer research history with hundreds of human trials, but results have been mostly disappointing — a cautionary parallel for fisetin, which has far stronger preclinical senolytic potency but very early human evidence.
Fisetin vs Kaempferol: Structurally Similar Flavonoid Comparison
Fisetin and kaempferol are structurally similar flavonols differing by a single hydroxyl group. In the 2018 senolytic screening, fisetin showed substantially stronger senolytic activity than kaempferol. The catechol group in fisetin's B-ring is hypothesized to be critical for BCL-xL binding. Kaempferol is far more abundant in the diet (kale, spinach, tea) but has weak senolytic activity and very limited human clinical data.
Healthy Aging Support Framework: Research-Informed Approach with Fisetin
Healthy aging is a multifactorial process influenced by genetics, lifestyle, environment, and accumulated cellular damage. This framework outlines the evidence-based pillars of healthy aging support and contextualizes where fisetin research fits within this broader landscape. IMPORTANT: This is an educational framework, not a treatment protocol. Fisetin is not proven to slow aging in humans. The foundation of healthy aging is well-established lifestyle interventions, not supplements.
Vascular Health Support Framework: Fisetin Research Context
Vascular health is fundamental to healthy aging and cardiovascular disease prevention. This framework outlines evidence-based approaches to maintaining vascular function and places the emerging fisetin clinical trial research in proper context. IMPORTANT: Fisetin is NOT a cardiovascular treatment. This framework emphasizes proven interventions. Fisetin research is included for educational context only.
Anti-Inflammatory Lifestyle Framework: Fisetin Research Context
Chronic low-grade inflammation ('inflammaging') is implicated in virtually every age-related disease. This framework outlines evidence-based strategies for reducing chronic inflammation and contextualizes fisetin's preclinical anti-inflammatory research. IMPORTANT: Fisetin is not a proven anti-inflammatory agent in humans. This framework prioritizes evidence-based interventions. Fisetin research is included for educational context only.